This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Study Sponsored By Medidata Solutions Identifies Up To $5 Billion In Potential Clinical Trial Cost Savings

Stocks in this article: MDSO

The results of a new research study performed by researchers at the Center for the Study of Drug Development at Tufts University School of Medicine and sponsored by Medidata Solutions (NASDAQ: MDSO) found that clinical data gathered from 25 percent of the procedures administered to patients may be unnecessary – and, in the aggregate, are responsible for $3-5 billion in overall clinical trial costs annually.

With clinical trials increasing in complexity, cost and difficulty to execute, life science organizations are under growing pressure to identify opportunities to reduce costs and safely improve R&D efficiencies. Procedures identified as non-core to the protocol may represent opportunities for pharmaceutical companies to streamline their trials and significantly reduce clinical trial budgets.

Presented today by the study’s principal investigator Ken Getz at the Drug Information Association’s (DIA) Annual Meeting, the study was conducted over an eight month period and is based on data from 15 international sponsor companies of all sizes. Study participants and Getz’s team used a version of Medidata Designer® customized for the research study to collect and analyze more than 115 clinical trial protocols and categorize more than 22,000 medical procedures. The costs of “core” procedures – those supporting study end-points or safety objectives – and “non-core” procedures were measured using Medidata’s extensive benchmarked clinical trial cost database.

“This study is groundbreaking in that it links, for the first time, clinical trial economics to protocol complexity,” said Getz, senior research fellow and research assistant professor at CSDD. “The results have been eye-opening for participating companies and will no doubt serve as a jumping off point for pharmaceutical and biotechnology companies to examine ways to reduce the number of non-core procedures to improve clinical trial efficiency and substantially reduce study budgets.”

Key study findings include:

  • Approximately 25% of all clinical trial procedures are considered non-core, i.e. are not directly tied to the trial end-points as agreed upon prior to the study by the U.S. FDA for demonstrating the safety and efficacy of the drug or therapy in question.
  • The non-core procedures represent roughly 20% of a clinical trial’s budget – an estimated $1 million in non-core procedure costs per clinical study.
  • Considering the number of studies conducted annually, physician-related costs associated with non-core procedures total $2-4 billion a year across the industry.
  • These procedures also increase the total burden of the clinical trial, requiring data management, monitoring, statistical analysis etc. Including these related trial costs, the non-core procedures represent an estimated $3-5 billion each year.

Marla Curran, director of clinical statistics and doctor of public health (DrPH) in biostatistics at GlaxoSmithKline (GSK), was part of the study working group and has driven efforts to increase efficiency across GSK trials. She views the study as one of the first to reveal actionable ways to cut clinical development costs without sacrificing safety or quality.

  • “By distinguishing between core and non-core procedures early on in the trial process, this research underscores the critical roles study design and protocol development play in overall clinical trial costs,” said Curran. “Even with this study’s conservative estimate of the procedures organizations could potentially eliminate, it’s clear that the industry can take a closer look at trial design to improve efficiencies while still meeting regulatory requirements.”

Medidata Designer was key to the Tufts CSDD team’s ability to collect information for the study, as it is the only tool to offer clinical trial sponsors visibility into cost and complexity metrics, as well as the structuring capabilities crucial for identifying unnecessary procedures during the study design stage.

  • “For years, we have been emphasizing that the effectiveness of any trial starts with a strong study design,” said Glen de Vries, president, Medidata Solutions. “Through the use of Designer, this study emphasizes the increasing role technology, and the expertise around it, will continue to play in helping drug developers design, conduct and manage efficient and effective clinical trials.”

The Center for the Study of Drug Development at Tufts University School of Medicine provides economic, policy and strategic data and analyses to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization.

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs